Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III , Double‐Blind, Randomized Controlled Trial

Published:2019-08-28 Issue:11 Volume:71 Page:1788-1800
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Fleischmann Roy¹^ORCID,Pangan Aileen L.²,Song In‐Ho²,Mysler Eduardo³,Bessette Louis⁴,Peterfy Charles⁵,Durez Patrick⁶,Ostor Andrew J.⁷,Li Yihan²,Zhou Yijie²,Othman Ahmed A.²^ORCID,Genovese Mark C.⁸^ORCID

Affiliation:

1. University of Texas Southwestern Medical Center and Metroplex Clinical Research Center Dallas

2. AbbVie North Chicago Illinois

3. Organización Medica de Investigación Buenos Aires Argentina

4. Laval University Quebec Canada

5. Spire Sciences Inc. Boca Raton Florida

6. UCL Saint‐Luc Brussels Belgium

7. Cabrini Medical Center Melbourne Victoria Australia

8. Stanford University School of Medicine Palo Alto California

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41032

Reference50 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

3. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

4. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry

5. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Cited by 338 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis;Nature Reviews Rheumatology;2024-09-06

3. Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study;Rheumatology and Therapy;2024-08-23

4. Blockade of rheumatoid arthritis synovial fluid-induced sensory neuron activation by JAK inhibitors;2024-08-19

5. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy;International Journal of Molecular Sciences;2024-07-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3